Endometrial cancer: statin use tied to lower VTE risk

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Statin use was associated with decreased risk for venous thromboembolism (VTE) in women with endometrial cancer.
  • Aspirin or statin+aspirin use did not lower risk for VTE.

Why this matters

  • Gynecologic cancers are associated with an increased risk of venous thromboembolism.
  • If confirmed in prospective studies, statins may reduce risk for VTE in obese women and those with aggressive tumors.

Study design

  • Multi-center study of 2527 women with primary endometrial cancer during 2000-2015.
  • 15.5% of patients received statin and 8.7% received aspirin.
  • Funding: Ensign Endowment for Gynecologic Cancer Research.

Key results

  • Median follow-up time, 43.0 months.
  • 132 women were diagnosed with VTE; 5-year cumulative incidence rate, 6.1%.
  • The most common events were deep vein thrombosis (DVT, 59.8%), followed by DVT+pulmonary embolism (PE; 23.5%), and PE (16.7%).
  • Statin use was associated with 58% lower risk for VTE vs non-use (2.5% vs 6.7%; aHR, 0.42; P=.030).
  • The impact of aspirin on VTE risk was not statistically significant (P=.24).
  • No significant joint effect of dual statin and aspirin use was observed (Pinteraction=.090).
  • Prognostic factors for statin VTE risk-reduction benefit included obesity, absence of diabetes mellitus, type II histology, and recurrent disease (all Pinteraction<.05>

Limitations

  • Retrospective design.